We welcome talks from early oncology investors that could supplement the team as well as potential commercialisation partners.

We have demonstrated PoC, a functioning prototype, solid idea, relevant competence in the core team, and protected IP. We applied for pre-seed funding to extend the runway to conduct MVP demonstration as a standalone product in a clinical setting (to take us to TLR 6-7) and to generate a detailed business plan that will lay the foundation for a high-potential spin-off company.

The PeptiCHIP platform can be easily integrated into existing analysis workflows and does not require extensive training to operate. Unlike any other method, the sample amounts required by PeptiCHIP are compatible with current clinical tumor biopsy practices. This permits taking the best-in-class PeptiCHIP purification process close to the patient’s bedside using a highly scalable business model based on a product/kit consumable. In addition to neoantigens, it can also be applied other types of antigens, such as those involved in autoimmune diseases.

Replicability of the PeptiCHIP microchip-based immunopurification protocol has been demonstrated with patient-derived dissolved tumor scarce tissue samples and patient-derived organoids with as little as 6 million cells in the PoC study currently under review: https://www.researchsquare.com/articl…

PeptiCHIP reduces the consumption of tumor sample, a significant limitation in the current state-of-the-art, which increases applicability of neoantigen identification to a wider range of cancers and reduces patient discomfort considerably. As a result, it permits the development of more effective personalised therapies, especially in combination with checkpoint inhibitors, that are tailored to particular cancers, their subtypes or even individual patients. The process is also more ecological, since the microchip format helps reduce the consumption of reagents significantly. Reductions in the time used on heavy laboratory equipment and shorter duration of analysis lower associated energy consumption. Increases in the accuracy of neoantigen identification reduce efforts spent on false leads during immunotherapy development, improving the efficience and cost-effectiveness of associated R&D projects.